You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨復宏漢霖收漲12.32% 股價創逾3年新高 公司啓動PD-L1 ADC藥物HLX43第5項二期臨牀
格隆匯 03-06 20:58

復宏漢霖(2696.HK)今日繼續強勢拉昇,盤中一度大漲13.39%至31.75港元,股價創2021年12月以來逾3年新高;最終收漲12.32%報31.45港元,全天成交1.15億港元,最新市值170.93億港元。該股去年累漲超70%,今年整體延續漲勢,於1月23日盤中觸及年內低點15.2港元後迅速回升,迄今不到一個半月的時間已大幅反彈約1.07倍。消息面上,復宏漢霖近日在日本東京成功舉辦HLX22-GC-301研究線下研究者會,聚焦公司在研創新型抗HER2單抗HLX22聯合曲妥珠單抗及化療一線治療HER2陽性晚期胃癌的國際多中心III期臨牀試驗(HLX22-GC-301)。此次會議是公司首次日本線下研究者會,也是公司深化在日佈局的重要一步,彰顯了公司以高質量創新撬動全球市場的決心。此外,復宏漢霖近期在clinical trials網站上登記了PD-L1 ADC藥物HLX43,聯合其PD-1抗體Serplulimab,在多種實體瘤患者啓動一項Ib/II 臨牀試驗NCT06848699,計劃2025年上半年啓動,入組人數爲105例。這也是該款藥物啓動的第5個二期臨牀,也是全球首個PD-L1 ADC+PD-1聯合療法,未來值得期待。(格隆匯)

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account